UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

~~March~~April 3022, 2022

Commission File Number: 001 - 38178

Zealand Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

Sydmarken 11

2860 Søborg (Copenhagen)
Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x                   ¨ Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Furnished as Exhibit 99.1 to this Report on Form 6-K is a company announcement of Zealand Pharma ~~A/S~~launches orlong-term ~~the~~incentive ~~Company,~~program ~~dated March 20,~~for ~~2020,~~Zealand’s ~~informing~~Board of ~~transactions~~Directors ~~in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities. Exhibits 99.2, 99.3 and 99.4 are supporting documentation~~ for ~~these transactions~~2022.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Zealand Pharma A/S

By:	/s/ Matthew Dallas

	Name:	Matthew Dallas
	Title:	Chief Financial Officer

Date: ~~March~~April 3022, 2022

EXHIBIT INDEX

Exhibit No.		Description
99.1		~~Press~~Company ~~Release~~announcement – No. 14/ 2022

Filing Compare · Zealand Pharma A/S